



<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

**Note to Readers: *In the event of any inconsistency between this document and the legislation that governs chiropractic and naturopathic practice in Nova Scotia, the legislation prevails.***

---

## 1. INTRODUCTION

The Nova Scotia Chiropractic and Naturopathic Regulator (NSCNR) is the regulatory authority for the practice of chiropractic and naturopathy in the Province of Nova Scotia.

This Standard of Practice establishes the minimum requirements for ND Registrants who perform immediate-use compounding or the aseptic preparation of sterile products for administration as part of authorized naturopathic care.

This Standard applies whenever an ND Registrant prepares, mixes, dilutes, combines, transfers, accesses, or otherwise handles sterile drugs, substances, solutions, preparations, containers, devices, or closed sterile systems for immediate administration to a single identified patient. This includes, but is not limited to, preparation associated with Injection Therapies, Intravenous Therapy, Ozone and Oxidative Therapies, Autologous Blood Products, and any other authorized procedure requiring the aseptic handling of sterile products.

***This Standard must be read together with the NSCNR Standard of Practice: In-Office Use Dispensing and any applicable Reserved Practice Permit standard governing the administration route or procedure being performed.***

## 2. APPLICATION AND ADMINISTRATION

This Standard of Practice shall apply to all naturopathic doctors registered and holding an active naturopath license with the NSCNR (the “**ND Registrant**” or collectively the “**ND Registrants**”).

The administration and application of this Standard of Practice shall be the responsibility of the Registrar. Should the NSCNR become aware of any alleged breach or noncompliance with this Standard of Practice, it may take any action it considers appropriate, including but not limited to:

- a. contacting a Registrant to request the immediate remedy of any suspected breach or non-compliance;
- b. filing a formal complaint under the *Regulated Health Professions Act* regarding the suspected breach or non-compliance as professional misconduct; and/or
- c. immediate suspension or revocation of Reserved practice permit.

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

### 3. OBJECTIVES

The objectives of this Standard are to uphold public interest and safety by:

- a) ensuring immediate-use compounding and aseptic preparation of sterile products are performed only by competent and authorized ND Registrants;
- b) establishing clear requirements for the aseptic access, preparation, handling, mixing, dilution, transfer, and immediate administration of sterile drugs, substances, solutions, preparations, containers, devices, and closed sterile systems;
- c) defining appropriate boundaries for immediate-use compounding and aseptic preparation of sterile products to prohibit manufacturing, batching, storage, advance preparation, practitioner-made inventory, office-made inventory, sterilization of non-sterile products, or pharmacy-level compounding activities;
- d) clarifying that this Standard applies across authorized naturopathic procedures where sterile products are prepared, accessed, mixed, diluted, transferred, or otherwise handled, including Injection Therapies, Intravenous Therapy, Ozone and Oxidative Therapies, Autologous Blood Products, and other applicable Reserved Practices; and
- e) supporting safe, ethical, and evidence-informed patient care through proportionate infection prevention and aseptic practice standards.

### 4. DEFINITIONS

The following terms have the following meanings when used in this Standard of Practice:

#### **Authorized Source**

A supplier from which ND Registrants may obtain drugs, sterile solutions, and related devices for in-office use, including:

- a) a manufacturer, packager/labeller, importer, distributor, or wholesaler that is authorized under applicable federal and provincial law to sell or distribute the product in Canada; and/or
- b) a pharmacy licensed under provincial law that is authorized to compound and supply compounded preparations (including sterile preparations), in accordance with applicable pharmacy standards and requirements.

#### **Autologous Blood Products**

Biologic solutions derived from the patient's own blood, including Platelet-Rich Plasma (PRP) or an NSCNR-approved equivalent.



<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

**Compounding** has the same meaning as the Chiropractic and Naturopathy Regulations, defined as the mixing of 2 or more ingredients, of which at least 1 is a drug, for the purpose of dispensing a drug or drugs, but does not include reconstituting a drug or drugs with only water.

“**drug**”, as per the Chiropractic and Naturopathy Regulations, has the same meaning as in the Food and Drugs Act (Canada) and includes any substance or combination of substances included in a prescription or incorporated in a schedule set out in the NSCNR Bylaws or Standards of Practice.

“**immediate-use compounding and aseptic preparation of sterile products**” means the aseptic access, preparation, mixing, dilution, admixing, pooling, reconstitution, transfer, or handling of commercially manufactured sterile drugs, substances, solutions, preparations, containers, or devices, or sterile preparations supplied by an Authorized Source, at the point of care for immediate administration to a single identified patient during a single clinical encounter. This may occur in connection with authorized Injection Therapies, Intravenous Therapy, Ozone and Oxidative Therapies, Autologous Blood Products, or other procedures requiring sterile products, sterile devices, closed sterile systems, or aseptic handling.

For clarity, immediate-use compounding and aseptic preparation of sterile products does not include manufacturing, batching, storage, advance preparation, pharmacy-level compounding, sterilizing non-sterile products, or creating practitioner-made or office-made inventory.

**Injection Therapies** are Reserved Practice clinical activities that involve the administration of a substance into the body by penetrating the skin or a mucous membrane using a sterile needle or similar device, including subcutaneous, intramuscular, intra-articular, and other injections into or around anatomical structures (e.g., ligaments, tendons, muscles, joints, or soft tissues), for diagnostic, therapeutic, preventive, or supportive purposes, performed by a ND Registrant in accordance with NSCNR authorization, applicable Standards of Practice, and infection prevention and control requirements.

**Intravenous Therapy (IV Therapy)** is a Reserved Practice clinical activity that involves the initiation, administration, monitoring, and termination of substances delivered into a vein by intravenous injection (“IV push”) and/or intravenous infusion via vascular access (e.g., peripheral intravenous catheter), for diagnostic, therapeutic, preventive, or supportive purposes.

**Professional Misconduct** has the same meaning as set out in the *Regulated Health Professions Act* and includes failing to maintain the standards of practice.



<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

**ND Registrant** means, for the purposes of this standard, a naturopathic doctor registered with the NSCNR and holding an active naturopath license.

**Reserved Practice** has the same meaning as set out in the *Chiropractic and Naturopathic Regulations* and means an activity, procedure or service within the scope of practice of naturopathy that:

- a) involves sufficient risk to the public, as determined by the Board;
- b) the Board requires licensed person to meet additional education, additional training or other requirements beyond an entry to practice level to engage in, and;
- c) a licensed person may engage in only with the approval of the registrar and may require a specific permit.

**“specific component training”** refers to structured education or supervised learning that provides the theoretical knowledge and practical competencies required to competently and safely administer a specific injectable substance or class of substances. Training may include workshops, supervised clinical practice, mentorship, coursework, or equivalent structured learning that includes both theory and application. Self-directed reading or self-study alone does not meet this requirement.

**“aseptic preparation of sterile products”** means the use of aseptic technique to access, prepare, mix, dilute, admix, pool, reconstitute, transfer, or otherwise handle sterile drugs, substances, solutions, preparations, containers, devices, or closed sterile systems for immediate administration to a single identified patient.

For clarity, this term refers to the Registrant’s aseptic handling or preparation process and does not mean that the Registrant is manufacturing, sterilizing, or creating sterile products in-office.

**“substance”** has the same meaning as set out in the *Chiropractic and Naturopathic Regulations* and means anything, other than a drug, permitted by scope of practice legislation or bylaws, that is publicly available, and which may include botanical tinctures, botanical powders, herbals, extracts, base creams, slaves, ointments, vitamins, minerals, and amino acids.

## 5. AREAS OF RESERVED PRACTICE PERMITS

Where immediate-use compounding or aseptic preparation of sterile products occurs in connection with a Reserved Practice, including Injection Therapies, Intravenous Therapy, Ozone

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

and Oxidative Therapies, or Autologous Blood Products, the ND Registrant must hold the applicable NSCNR Reserved Practice Permit(s).

Compliance with this Standard does not independently authorize a Registrant to administer a drug, substance, injection, infusion, ozone therapy, oxidative therapy, autologous blood product, or other Reserved Practice unless the Registrant holds the required authority, training, competence, and permit for that activity.

## 6. STANDARDS OF PRACTICE

### A. Requirements to perform Immediate-Use Compounding and Aseptic Preparation of Sterile Products

- a) Immediate-use compounding and aseptic preparation of sterile products are permitted only where the ND Registrant holds a current active naturopath license issued by the NSCNR:
  - i. holds any applicable Reserved Practice Permit(s), including for Injection Therapies, Intravenous Therapy, Ozone and Oxidative Therapies, and/or Autologous Blood Products, where the preparation, handling, or administration of the sterile product occurs in connection with those procedures;
  - ii. is able to provide evidence satisfactory to the Registrar of successful completion of one (1) of the following:
    - (a) Canadian Prescribing and Therapeutics Examination; or
    - (b) NSCNR Board-approved equivalent;
  - iii. is competent in aseptic technique and infection prevention and control; and
  - iv. performs the activity where they can provide evidence of personal training, and competence.

### B. Training and Competency of Immediate-Use Compounding of Injectable Solutions

- a) ND Registrants performing immediate-use compounding and aseptic preparation of sterile products must ensure personal competence in:
  - i. infection prevention and control;
  - ii. aseptic preparation, handling, and administration of sterile products used for injection, intravenous therapy, ozone and oxidative therapies, autologous blood products, or other authorized procedures, as applicable;
  - iii. recognition and management of adverse reactions; and
  - iv. emergency response appropriate to the clinical setting.

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

- b) ND Registrants must obtain additional specific training prior to introducing a new substance or class of substances into practice.
- c) ND Registrants who prepare, handle, or administer sterile products in connection with Injection Therapies, Intravenous Therapy, Ozone and Oxidative Therapies, Autologous Blood Products, or another Reserved Practice must hold the applicable current Reserved Practice Permit(s), including all training, competence, emergency preparedness, infection prevention and control, and continuing competence requirements.

### **C. General Standards for Immediate-Use Compounding and Aseptic Preparation of Sterile Products**

ND Registrants may perform immediate-use compounding and aseptic preparation of sterile products **only** where all of the following conditions are met:

- i. the preparation is for a single identified patient;
  - ii. the preparation occurs during a single clinical encounter;
  - iii. the preparation is prepared for prompt administration within no more than 60 minutes, and in accordance with manufacturer instructions, within the same clinical encounter;
  - iv. any prepared syringes or solutions are not stored;
  - v. if administration is delayed or interrupted, the preparation must be discarded;
  - vi. the preparation is not batched; and
  - vii. no inventory is created or maintained.
- b) ND Registrants may only access, prepare, mix, dilute, combine, transfer, or otherwise handle sterile products that are:
- i. sterile and obtained from an authorized source, including:
    - (a) a commercially manufactured sterile drug or solution; and/or
    - (b) a sterile preparation compounded and supplied by a licensed pharmacy in accordance with applicable pharmacy compounding standards;
  - ii. included on the NSCNR Approved Substances and Drugs for In-Office Use Schedule and authorized for use within naturopathic practice;
  - iii. used in compliance with manufacturer instructions for all substances, diluents, and devices; and
  - iv. consistent with the ND Registrant’s training, competence, and scope of practice.

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

- c) ND Registrants must obtain specific informed consent related to the substances or drugs compounded and in accordance with the **NSCNR Standard of Practice: Informed Consent**.
- d) ND Registrants must comply with **NSCNR Standard of Practice: Patient Record Management** and patient records must include details of immediate-use compounding, aseptic preparation of sterile products, and administration:
- I. the substance(s) and/or drugs prepared and administered;
  - II. dose, lot number, and expiry date;
  - III. route and site of administration;
  - IV. patient response and any adverse events; and
  - V. post-administration monitoring and follow-up.
- d) Immediate-use compounding and aseptic preparation of sterile products must be performed in accordance with the NSCNR Standard of Practice: Infectious Disease Prevention and Control and recognized aseptic technique and infection prevention and control principles appropriate to the procedure and clinical office setting.
- e) ND Registrants must:
- i. perform hand hygiene prior to accessing supplies, handling vials, and preparing or administering substances;
  - ii. use aseptic technique in all aspects of accessing, preparing, mixing, diluting, transferring, handling, and administering sterile products;
  - iii. ensure syringes and needles are single-use only and never reused;
  - iv. never administer medication from the same syringe to more than one patient;
  - v. never store needles or syringes unwrapped;
  - vi. not prepare syringes or administration sets in advance; and
  - vii. not use IV bags or solutions as a common source of supply for multiple patients.
- f) Where single-dose vials are used, ND Registrants must:
- i. enter once and be discarded immediately after use;
  - ii. use a new sterile syringe and needle for every vial;
  - iii. scrub the vial diaphragm with a minimum of 70% alcohol and allow it to dry prior to access; and
  - iv. not pool or reuse leftover contents.
- g) Where multidose vials are used, ND Registrants must:
- i. label the vial with the date of first entry;
  - ii. use a new sterile syringe and needle for every vial entry;

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

- iii. scrub the vial diaphragm with a minimum of 70% alcohol and allow it to dry prior to access;
  - iv. never leave a needle in a vial;
  - v. discard the vial immediately if sterility is questioned; and
  - vi. discard the vial according to manufacturer instructions or within 28 days of first entry, whichever is shorter.
- h) Immediate-use compounding and aseptic preparation of sterile products must occur on a clean, designated surface. The preparation area must be free from:
- i. used or contaminated equipment;
  - ii. unrelated supplies; and
  - iii. conditions that compromise aseptic technique.
- i) Immediate-use compounding and aseptic preparation of sterile products must not occur near sinks, waste disposal areas, or other locations where splash or contamination risk is present.

#### **D. Immediate-Use Preparation Standards of Autologous Blood Products**

- a) ND Registrants may only prepare or administer autologous blood products where the ND Registrant holds a current **Reserved Practice Permit for Autologous Blood Products**;
- b) Immediate-use compounding and aseptic preparation of sterile products may include the immediate-use preparation of autologous blood products, including Platelet-Rich Plasma (PRP), where such preparation is performed: using the patient’s own blood;
  - i. for administration to that same patient;
  - ii. during a single clinical encounter; and
  - iii. for immediate therapeutic use without storage, batching, or distribution.
- c) The preparation of autologous blood products is limited to processing and preparation activities necessary for immediate clinical use (within 30 minutes), including blood collection, separation, concentration, and transfer, and must be performed using commercially manufactured devices or systems approved for such use.
- d) The immediate-use preparation of autologous blood products under this Standard does not constitute manufacturing and does not include:
  - i. modification or alteration of blood products beyond device-supported processing;
  - ii. storage of prepared autologous blood products;

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

- iii. pooling or combining blood products from more than one patient; or
- iv. the creation or maintenance of practitioner-made or office-made inventory.

## 7. EXEMPTIONS

There are no applicable exemptions at this time.

## 8. RESTRICTIONS

Immediate-use compounding and aseptic preparation of sterile products does not authorize ND Registrants to: manufacture drugs or biologics;

- a) sterilize non-sterile substances;
- b) operate a sterile compounding service; or
- c) prepare compounded products for future use; or
- d) compound, prepare, or administer any drug or substance not authorized by the NSCNR Approved Substances and Drugs for In-Office Use Schedule, where such a schedule applies.

## 9. LEGISLATIVE CONTEXT

[Regulated Health Professions Act \(2023\)](#)

[Regulated Health Professions General Regulations](#)

Regulations Respecting Chiropractic and Naturopathy

Nova Scotia Chiropractic and Naturopathic Regulator Bylaws

## 10. ADDITIONAL RELEVANT STANDARDS OF PRACTICE:

Registrants are advised that all NSCNR Standards of Practice apply, including but not limited to, specific application of:

- Patient Record Management
- Informed Consent
- First Aid
- Emergency Readiness
- Infectious Disease Prevention and Control
- Immediate Use Compounding
- Reserved Practice Permit: Ozone and Oxidative Therapies
- Reserved Practice Permit: Autologous Blood Products

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

## Schedule A – ND Approved Substances and Drugs for Immediate In-Office Use

### Interpretation

Inclusion of a substance or drug on this Schedule does not, on its own, authorize a Registrant to obtain, possess, prepare, compound, dispense, or administer that substance or drug. The Registrant must also comply with all applicable legislation, NSCNR Standards of Practice, scope of practice requirements, Reserved Practice Permit requirements, manufacturer instructions, and individual competency requirements.

Where a substance appears with more than one route of administration, only those routes within the Registrant’s authority, applicable permit, and competence may be used.

All substances and drugs listed in this Schedule are for immediate in-office use only, unless otherwise specified.

### Part 1 - IV Nutrients, Amino Acids, Vitamins, and Minerals

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Amino Acid	Acetylcysteine	IV	IV nutrient infusion	Must be used with other amino acids.
Nutraceutical	Adenosine monophosphate	IV	IV nutrient infusion	
Nutraceutical	Adenosine triphosphate	IV	IV nutrient infusion	
Amino Acid	Alanine	IV	IV nutrient infusion	Must be used with other amino acids.
Nutraceutical	Alpha Lipoic Acid	IV	IV nutrient infusion	
Amino Acid	Arginine	IV	IV nutrient infusion	Must be used with other amino acids.

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Vitamin	Ascorbic Acid (Vitamin C)	IV	IV nutrient infusion	
Amino Acid	Aspartic Acid	IV	IV nutrient infusion	Must be used with other amino acids.
Vitamin	Vitamin B1 (Thiamine)	IV or IM injection	IV/IM nutrient therapy	
Vitamin	Vitamin B2 (Riboflavin)	IV or IM injection	IV/IM nutrient therapy	
Vitamin	Vitamin B3 (Niacinamide)	IV or IM	IV/IM nutrient therapy	
Vitamin	Vitamin B5 (Pantothenic Acid)	IV or IM	IV/IM nutrient therapy	
Vitamin	Vitamin B6 (Pyridoxine)	IV or IM	IV/IM nutrient therapy	
Vitamin	Vitamin B12 in all forms	IV or IM or SC injection	IV/IM/SC nutrient therapy	
Vitamin	Biotin	IV	IV nutrient infusion	
Mineral	Calcium Chloride	IV	IV mineral therapy	
Nutraceutical	Calcium EDTA	IV	In-office procedural use	
Mineral	Calcium Gluconate	IV	IV mineral therapy	
Mineral	Calcium Glycerophosphate	IV	IV mineral therapy	

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Nutraceutical	Choline	IV or IM	IV/IM nutrient therapy	
Mineral	Chromium	IV	IV mineral therapy	
Mineral	Copper Sulfate	IV	IV mineral therapy	
Mineral	Copper II Chloride	IV	IV mineral therapy	
Vitamin	Folate in all forms	IV or IM injection	IV/IM nutrient therapy	
Amino Acid	Glutamine	IV	IV nutrient infusion	Must be used with other amino acids.
Amino Acid	Glutamic Acid	IV	IV nutrient infusion	Must be used with other amino acids.
Nutraceutical	Glutathione	IV or IM	IV/IM nutrient therapy	
Amino Acid	Glycine	IV	IV nutrient infusion	Must be used with other amino acids.
Amino Acid	Histidine	IV	IV nutrient infusion	Must be used with other amino acids.
Nutraceutical	Inositol	IV or IM	IV/IM nutrient therapy	
Amino Acid	Isoleucine	IV	IV nutrient infusion	Must be used with other amino acids.

**SP-ND001**

**Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections**

**Approved Date: Effective May 27, 2026**

**Amended: n/a**

**Next Review Date: 2029**

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Amino Acid	L-Tryptophan	IV	IV nutrient infusion	
Amino Acid	Leucine	IV	IV nutrient infusion	Must be used with other amino acids.
Amino Acid	Levocarnitine and its salts	IV	IV nutrient infusion	
Amino Acid	Lysine	IV or IM	IV/IM nutrient therapy	Must be used with other amino acids.
Mineral	Magnesium Sulfate	IV or IM	IV/IM mineral therapy	
Mineral	Magnesium Chloride	IV or IM	IV/IM mineral therapy	
Mineral	Manganese	IV	IV mineral therapy	
Nutraceutical	Methionine	IV or IM	IV/IM nutrient therapy	
Mineral	Molybdenum	IV	IV mineral therapy	
Nutraceutical	MSM	IV	IV nutrient infusion	
Nutraceutical	Nicotinamide Adenine Dinucleotide	IV or SC injection	IV/SC nutrient therapy	
Amino Acid	Ornithine	IV	IV nutrient infusion	Must be used with other amino acids.
Amino Acid	Phenylalanine	IV	IV nutrient infusion	Must be used with other amino acids.

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Nutraceutical	Phosphatidylcholine	IV	IV nutrient infusion	
Mineral	Potassium Chloride	IV	IV mineral therapy	Not more than 0.3 mEq/kg/hr; may not be administered on its own or by IV push.
Mineral	Potassium Phosphate	IV	IV mineral therapy	Not more than 0.3 mEq/kg/hr; may not be administered on its own or by IV push.
Amino Acid	Proline	IV	IV nutrient infusion	Must be used with other amino acids.
Mineral	Selenium	IV	IV mineral therapy	
Amino Acid	Serine	IV	IV nutrient infusion	Must be used with other amino acids.
Mineral	Sodium Bicarbonate	IV	IV mineral / buffer therapy	
Mineral	Sodium Iodide	IV	IV mineral therapy	Must be used with other minerals.
Mineral	Strontium and its salts	IV	IV mineral therapy	
Amino Acid	Taurine	IV	IV nutrient infusion	

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Amino Acid	Threonine	IV	IV nutrient infusion	Must be used with other amino acids.
Amino Acid	Tyrosine	IV	IV nutrient infusion	Must be used with other amino acids.
Mineral	Vanadium	IV	IV mineral therapy	
Vitamin	Vitamin A	IV or IM	IV/IM vitamin therapy	
Vitamin	Vitamin D	IV or IM	IV/IM vitamin therapy	
Vitamin	Vitamin E	IV	IV vitamin therapy	
Vitamin	Vitamin K1	IM	IM vitamin therapy	
Mineral	Zinc Chloride	IV	IV mineral therapy	
Mineral	Zinc Sulphate	IV	IV mineral therapy	

**Part 2 - IV Fluids and Injection Fluids**

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
IV Fluid	Dextrose	IV, IM, intra-articular, extra-articular, SC, intradermal	In-office procedural use	

**SP-ND001**

**Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections**

**Approved Date: Effective May 27, 2026**

**Amended: n/a**

**Next Review Date: 2029**

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Injection Fluid	Dextrose D50W	Intra-articular	Prolotherapy	
IV Fluid	Lactated Ringer's Solution	IV	IV fluid therapy	
Injection Fluid	Mannitol 25%	SC	Perineural injection fluid	
IV Fluid	Ringer's Solution (sodium, chloride, potassium and calcium)	IV	IV fluid therapy	
IV Fluid	Saline Solution	IV	IV fluid therapy	
IV Fluid	Sodium Chloride	IV	IV fluid therapy	IV with MAH.
Mineral	Sodium Citrate	SC, IM, IV, intra-articular	In-office procedural use	
IV Fluid	Sterile Water	IV	IV fluid therapy	Isotonic - must become hypertonic before injection.

### Part 3 - Iron Preparations

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Iron	Ferric derisomaltose	IV	In-office iron infusion	
Iron	Ferric gluconate	IV	In-office iron infusion	
Mineral	Ferrous Sulphate	IM	Iron therapy	Use Z track.

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Iron	Iron sucrose	IV	In-office iron infusion	
Iron	Saccharated Iron Oxide	IV	In-office iron infusion	Product-specific entry.
Iron	Ferric Sodium Gluconate Complex	IV	In-office iron infusion	Product-specific entry.
Iron	Ferric Derisomaltose	IV	In-office iron infusion	Product-specific entry.

#### **Part 4 - Corticosteroids and Procedural Injection Medications**

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Medication / Corticosteroid	Betamethasone	IM or intra-articular	In-office corticosteroid injection	
Medication	Bupivacaine	IM	In-office procedural use	
Medication / Corticosteroid	Dexamethasone	IM and intra-articular	In-office corticosteroid injection	Prohibited for ocular use.
Medication	Heparin	SC, IM, IV, intra-articular	In-office procedural use	Limited for use with PRP and MAH/Ozone with Reserved Practice Permit(s) applicable

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Nutraceutical	Hyaluronidase	SC	In-office procedural use	
Medication / Corticosteroid	Hydrocortisone	IM and intra-articular	In-office corticosteroid injection	
Medication	Lidocaine	IV, IM, intra-articular, extra-articular, SC, intradermal	In-office procedural use	
Nutraceutical	Methylene Blue	IV	In-office procedural use	
Medication / Corticosteroid	Methylprednisolone / Methylprednisolone acetate	IM or intra-articular	In-office corticosteroid injection	
Medication	Ondansetron	IV	Nausea	
Nutraceutical	Phosphatidylcholine with Deoxycholate	SC	In-office procedural use	
Medication	Procaine	SC, IM, IV, intra-articular, extra-articular, intradermal	In-office procedural use	
Medication / Corticosteroid	Triamcinolone acetonide / Triamcinolone hexacetonide	IM and intra-articular	In-office corticosteroid injection	
Corticosteroids	Methylprednisolone acetate (Depo-Medrol®)	IM or intra-articular	In-office corticosteroid injection	Product-specific entry.

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Corticosteroids	Triamcinolone acetonide (Kenalog®)	IM and intra-articular	In-office corticosteroid injection	Product-specific entry.
Corticosteroids	Triamcinolone hexacetonide (Aristospan® / Trispan®)	IM and intra-articular	In-office corticosteroid injection	Product-specific entry.
Corticosteroids	Betamethasone (Celestone Soluspan®)	IM or intra-articular	In-office corticosteroid injection	Product-specific entry.
Corticosteroids	Dexamethasone	IM and intra-articular	In-office corticosteroid injection	Product-specific entry.
Corticosteroids	Hydrocortisone	IM and intra-articular	In-office corticosteroid injection	Product-specific entry.

**Part 5 - Viscosupplementation / Hyaluronan Products**

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Nutraceutical / Hyaluronan	Hyaluronic Acid	IV and intra-articular	In-office viscosupplementation / procedural use	
Hyaluronan / Viscosupplementation	Durolane	Intra-articular	In-office viscosupplementation injection	Product-specific entry.
Hyaluronan / Viscosupplementation	Cingal	Intra-articular	In-office viscosupplementation injection	Product-specific entry.

<b>SP-ND001</b>
<b>Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections</b>
<b>Approved Date: Effective May 27, 2026</b>
<b>Amended: n/a</b>
<b>Next Review Date: 2029</b>

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Hyaluronan / Viscosupplementation	Monovisc	Intra-articular	In-office viscosupplementation injection	Product-specific entry.
Hyaluronan / Viscosupplementation	Synvisc / Synvisc-One	Intra-articular	In-office viscosupplementation injection	Product-specific entry.
Hyaluronan / Viscosupplementation	Orthovisc	Intra-articular	In-office viscosupplementation injection	Product-specific entry.
Hyaluronan / Viscosupplementation	SportVis	Intra-articular	In-office viscosupplementation injection	Product-specific entry.

#### Part 6 - Emergency Medications

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Emergency Medication	Atropine	IV	In-office emergency use	For use only during in-office emergency.
Emergency Medication	Diphenhydramine Hydrochloride	IV or IM	In-office emergency use	For use only during in-office emergency.
Emergency Medication	Epinephrine Hydrochloride	IM or SC	In-office emergency use	For use only during in-office emergency.

**SP-ND001**

**Standard of Practice: Immediate-Use Compounding and Aseptic Preparation of Sterile Products for Injections**

**Approved Date: Effective May 27, 2026**

**Amended: n/a**

**Next Review Date: 2029**

**Part 7 - Biologics / Specialized Procedures**

<b>Drug / Substance Class</b>	<b>Name of Substance</b>	<b>Permitted Route(s) of Administration</b>	<b>Permitted In-Office Purpose</b>	<b>Additional Information</b>
Other	Autologous blood products (PRP)	IV, IM, intra-articular, extra-articular, SC, intradermal	In-office procedural use	Requires applicable Reserved Practice Permit.
Nutraceutical	DMP5	IV	In-office procedural use	
Nutraceutical	DMSA	IV	In-office procedural use	
Nutraceutical	DMSO	IV	In-office procedural use	
Nutraceutical	EDTA	IV	In-office procedural use	
Nutraceutical	Hydrochloric Acid	IV	In-office procedural use	
Nutraceutical	Hydrogen Peroxide 3%	IV	In-office procedural use	
Other	Ozone	IV, IM, intra-articular, extra-articular, SC, intradermal	In-office procedural use	Requires applicable Reserved Practice Permit.
Nutraceutical	Viscum Album	IV or SC injection or intra-articular	In-office procedural use	Used for arthritis.